<DOC>
	<DOCNO>NCT00988806</DOCNO>
	<brief_summary>The purpose study determine whether treatment strategy long-term intermittent every 30 day , continuous intravenous infusion 24 hour Levosimendan , associate optimal contemporary treatment advance heart failure reduce incidence admission heart failure worsen 12 month follow , compare strategy base solely optimal contemporary treatment advance heart failure .</brief_summary>
	<brief_title>Long-Term Intermittent Administration Levosimendan Patients With Advanced Heart Failure</brief_title>
	<detailed_description>Aims : To evaluate efficacy safety long-term , intermittent intravenous administration 24 hour Levosimendan treatment advance heart failure . Main end-point : incidence admission due decompensation , define first admission emergency service hospitalization 12 hour due heart failure worsen . Secondary end-points : major cardiac event , serious adverse event , change NYHA scale baseline , 30 day , 6 12 month ; effect inflammatory neurohormonal activation heart failure , identify factor associate well survival patient , quality life , cost-effectiveness treatment . Study Design : Prospective , randomize , double-blind placebo control trial . Scope study : patient advance heart failure . Study Subjects : Patients 18 year old advance HF etiology , least one admission acute decompensation treat treatable Levosimendan within 6 month prior randomization . Interventions : 24-hour infusion every 30 day Levosimendan placebo addition optimal pharmacological treatment HF 12 month . Determinations : clinical monitoring , protocol-specified analytical determination , echocardiographic assessment , invasive hemodynamic assessment , functional assessment 6 min walk test corridor , quality life assessment baseline , 30 day , 6 month 12 month .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Age 18 Severe symptom heart failure dyspnea and/or fatigue rest minimal effort ( functional class III IV NYHA ) Episodes fluid retention ( pulmonary systemic venous congestion , peripheral edema ) and/or low cardiac output rest ( peripheral hypoperfusion ) objective evidence severe cardiac dysfunction determine presence least one following : Left ventricular ejection fraction &lt; /= 30 % A severe impairment cardiac function echocardiography Doppler transmitral flow pattern pseudonormal restrictive . A left ventricular filling pressure elevate ( PCP &gt; 16 mmHg / DBP average &gt; 12 mm Hg pulmonary artery catheterization ) Levels BNP NTproBNP high absence noncardiac cause . Severe impairment functional capacity evidence one following : Inability exercise A distance &lt; 300 less woman / patient &gt; /= 75 year 6minute walk test A test myocardial oxygen consumption &lt; 1214 ml / kg / min . &gt; /= 1 prior history HF hospitalization previous 6 month Presence criterion despite attempt optimize therapy include diuretic , inhibitor reninangiotensinaldosterone system betablockers , unless drug tolerate contraindicate , cardiac resynchronization therapy indicate . consent participate study . Levosimendan allergy hypersensitivity . Severe renal impairment ( creatinine clearance &lt; 30 ml / min ) . Severe liver impairment . History autoimmune disease . Pregnancy . Women childbearing age use adequate contraception ( hormonal , IUD , barrier + spermicide ) Heart disease significant obstruction ventricular fill empty . Severe hypotension ( Systolic &lt; 90 mmHg ) . Tachycardia &gt; 120 bpm history torsion point type ventricular tachycardia . Severe concomitant disease decrease shortterm prognosis . Inability give inform consent . Participation another study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Advanced heart failure</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Intermittent long-term infusion</keyword>
</DOC>